Baidu
map

Clin Nutr:太可怕了!维生素D缺乏可能影响艾滋病患者HAART疗效!

2015-11-18 chenshuo译 MedSci原创

http://www.medicalnewstoday.com/articles/302693.php

在以往的研究中,已经得知HIV病毒在人体内的作用机制是攻击人体的CD4细胞,或T细胞(白细胞的一种,帮助免疫系统对外来抗原进行清除起着重要的作用)。



目前,治疗艾滋病患者最常见的方法是抗逆转录病毒疗法(HAART),可以尽可能地恢复及加强患者的免疫功能,但有研究发现,人体内维生素D的含量较低可能对抗逆转录病毒疗法有消极的影响。

这是近日在临床营养学杂志上最新发表的一篇文章的观点。

为了证明维生素D对HAART疗法的疗效是否有影响,来自于雅典佐治亚大学流行病学和生物统计学助理教授Amara Ezeamama和他的同事对398名HIV阳性的成年人患者进行了18个月的调查研究。
统计得到的数据包括参与试验者在这段时间内维生素D的水平和他们体内的CD4细胞计数量(在0、3、6、12和18个月时)。

研究人分析数据发现,在研究期间CD4细胞计数的变化与维生素D的基线水平紧密相关。
同时,研究团队还发现,维生素D水平较高的试验者相对于水平低的试验者,他们的免疫功能恢复的程度也相对高点。

最后,研究人员认为,补充维生素D可能有助于正在进行HAART治疗的HIV阳性患者的免疫功能恢复,但仍需要专门设计一项研究来验证该结论。

Amara Ezeamama教授说:

“当今的时代,对艾滋病的患者来说是充满希望的。我们都知道,目前国际上的医疗水平,艾滋病患者可以依靠医疗手段存活几十年以上或更长的时间。但是,如果我们能够了解限制艾滋病患者治疗效果的因素,我们就可以进一步地延缓疾病的进展,从而提高艾滋病患者的生活质量并延长生命。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958051, encodeId=4b731958051c7, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Jul 01 07:08:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51534, encodeId=0e1b515345a, content=这个也可以有啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Jan 03 21:37:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51535, encodeId=af6f5153537, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Jan 03 21:37:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49574, encodeId=9afd495e403, content=很值得, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:07:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356031, encodeId=1dde1356031b1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Nov 20 08:08:00 CST 2015, time=2015-11-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958051, encodeId=4b731958051c7, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Jul 01 07:08:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51534, encodeId=0e1b515345a, content=这个也可以有啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Jan 03 21:37:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51535, encodeId=af6f5153537, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Jan 03 21:37:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49574, encodeId=9afd495e403, content=很值得, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:07:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356031, encodeId=1dde1356031b1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Nov 20 08:08:00 CST 2015, time=2015-11-20, status=1, ipAttribution=)]
    2016-01-03 xyfg98

    这个也可以有啊

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1958051, encodeId=4b731958051c7, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Jul 01 07:08:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51534, encodeId=0e1b515345a, content=这个也可以有啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Jan 03 21:37:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51535, encodeId=af6f5153537, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Jan 03 21:37:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49574, encodeId=9afd495e403, content=很值得, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:07:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356031, encodeId=1dde1356031b1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Nov 20 08:08:00 CST 2015, time=2015-11-20, status=1, ipAttribution=)]
    2016-01-03 xyfg98

    值得关注

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1958051, encodeId=4b731958051c7, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Jul 01 07:08:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51534, encodeId=0e1b515345a, content=这个也可以有啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Jan 03 21:37:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51535, encodeId=af6f5153537, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Jan 03 21:37:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49574, encodeId=9afd495e403, content=很值得, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:07:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356031, encodeId=1dde1356031b1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Nov 20 08:08:00 CST 2015, time=2015-11-20, status=1, ipAttribution=)]
    2015-12-27 忠诚向上

    很值得

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1958051, encodeId=4b731958051c7, content=<a href='/topic/show?id=a2cd868009b' target=_blank style='color:#2F92EE;'>#艾滋病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86800, encryptionId=a2cd868009b, topicName=艾滋病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c83329, createdName=10518093zz, createdTime=Fri Jul 01 07:08:00 CST 2016, time=2016-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51534, encodeId=0e1b515345a, content=这个也可以有啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Jan 03 21:37:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=51535, encodeId=af6f5153537, content=值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fe261399236, createdName=xyfg98, createdTime=Sun Jan 03 21:37:00 CST 2016, time=2016-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49574, encodeId=9afd495e403, content=很值得, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 20:07:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356031, encodeId=1dde1356031b1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Nov 20 08:08:00 CST 2015, time=2015-11-20, status=1, ipAttribution=)]
    2015-11-20 zhaojie88

相关资讯

LANCET:HIV感染患者,服用替诺福韦前体药物出现的药物副作用更少

背景:抗逆转录病毒治疗方案中若含有替诺福韦酯片(tenofovir disoproxil fumarate,tenofovir DF)则会导致患者出现肾毒性,并降低机体骨密度。Tenofovir alafenamide是替诺福韦的前体药物,可使机体替诺福韦离子浓度减少90%,从而减少该药物对机体的毒副作用。该研究的目的旨在评估若病人将tenofovir DF更换为Tenofovir alafena

FDA:抗击艾滋病的重磅武器来啦!

FDA批准,制药商吉利德科学公司生产的药物 Genvoya可以作为12岁及以上的HIV患者的治疗用药。Genvoya是固定剂量的Elvitegravir、cobicistat、emtricitabine和tenofovir alafenamide等药物的组合。FDA要求,药物的使用人群限于12岁及以上的患者,体重至少达到35公斤(77磅),之前从未针对艾滋病毒进行治疗过,或者艾滋病毒感染但病毒处于

STM:研究HIV疫苗的免疫反应为疫苗研发提供线索

最新的研究结果指出,科学家们取得了免疫反应相关的新信息,后者则可能与防止艾滋病毒感染相关,能够提供新的策略来开发一种艾滋病疫苗。RV144试验的结果发表在2009年,为HIV疫苗功效提供了第一个信号——疫苗接种者中艾滋病病毒感染减少31%。从那时起,一个国际研究协会一直在进行研究并寻找出相关的分子线索以解释为什么疫苗具有这种温和的保护作用。一篇新的综述对HIV疫苗的报道进行了概述,提示预防HIV疫

Lancet:HIV阳性妇女联合使用避孕药和避孕方法对妊娠率的影响

背景:有研究指出依法韦伦能减少避孕植入物的有效性。我们旨在研究在不同HIV阳性妇女中,使用各种避孕方法与使用依法韦仑或奈韦拉平抗逆转录病毒疗法(ART)方案对妊娠率是否有影响。方法:研究人员进行回顾性的HIV女性年龄为15-45岁,她们来自于西部肯尼亚的由家庭AIDS保健和教育服务支持的19个HIV照看机构,时间是从2011年1月1到2013年12月31.研究人员以临床诊断出怀孕为基本指标。其采用

Ann Intern Med:男男做爱,除了HIV,HBV感染率也很高

男人与男人做爱 (男男性行为者)(MSM)不仅HIV感染风险高,HBV感染风险也不低。 关于对HIV感染的男性、HIV未感染但同男人做爱的男性(MSM),进行高效抗逆转录病毒治疗 (HAART)对HBV感染发生率的影响的研究目前还没有。研究者对MSM(HIV感染者或高风险者)进行了一项观察性队列研究。纳入了2375名未感染HBV的MSM对象,以探究MSM人群在HAART治疗前和治疗时HBV发生情况

Ann Intern Med:HIV患者的肿瘤发生情况统计

癌症在HIV患者中发生率越来越高。研究者在1996-2009年间,对北美艾滋患者进行了一项队列研究,调查HIV患者累积癌症发生率。该研究纳入了86 620名HIV患者和196 987名非艾滋成年人。研究者们探究了对象在75岁时不同癌症类型的累积发生率,以及发生率趋势。研究数据显示,对于HIV人群和非HIV人群,其癌症累积发生率如下:kaposi肉瘤 4.4% vs 0.01%、非霍奇金淋巴瘤 4.

Baidu
map
Baidu
map
Baidu
map